Skip to main content

Table 2 Genes mapping to the duplicated genomic region

From: The multiple de novo copy number variant (MdnCNV) phenomenon presents with peri-zygotic DNA mutational signatures and multilocus pathogenic variation

Sample

Locus

dnCNV Coordinates(GRCh38)

dnCNV type

OMIM disease genes (associated trait MIM#) mapping in duplicated region

Number of genes(pLi > 0.9)

Total number of genes overlapping duplication region

ACMG classification evidence*

ACMG classification

BAB9637

4q31.22q31.23

chr4:147494740-148399180

DUP

EDNRA (#616367, AD); NR3C2 (#177735, AD)

2

10

1A, 2J, 3A, 4D

VUS

BAB9637

5q35.2q35.3

chr5:176449583-177376826

DUP

SNCB (#127750, AD); NSD1 (#117550, AD)

3

23

1A, 2A

Pathogenic

BAB9637

6p24.2p24.1

chr6:11481309-12522879

DUP

EDN1 (#612798, AD; #615706, AR)

1

10

1A, 3A, 4D

VUS

BAB9637

10q26.13q26.2

chr10:124920875-125841697

DUP

UROS (#263700, AR); MMP21 (#616749, AR)

1

16

1A, 3A, 4D

VUS

BAB9637

12q13.2q13.3

chr12:55986511-56885590

DUP

MIP (#615274, AD), ERBB3 (#133180, AD; #607598, AR),SMARCC2 (#618362, AD), RPS26 (#613309, AD), SLC39A5 (#615946, AD), SUOX (#272300, AR), STAT2 (#618886, AR; #616636, AR)

8

40

1A, 2H, 3B, 4B

VUS

BAB9637

13q33.3q34

chr13:109406834-110341135

DUP

COL4A1 (#180000, AD; #611773, AD; #175780, AD; #618564, AD), COL4A2 (#614483, AD), IRS2 (#125853, AD)

1

8

1A, 3A, 4D

VUS

BAB9637

14q21.1

chr14:40568596-41479705

DUP

 

0

0

1B

VUS

BAB9637

21q21.3

chr21:28158347-29192300

DUP

 

1

12

1A, 3A, 4D

VUS

BAB3097

1p36.22p36.13

chr1:10115497-16283149

DUP

KIF1B (#118210, AD; #171300, AD; #256700), PEX14 (#614887, AR), TARDBP (#612069, AD), MASP2 (#613791, AR),  MTOR (#616638, AD), UBIAD1 (#121800, AD), MAD2L2 (#617243, AR), MTHFR (#236250, AR), CLCN6 (#619173, AD), NPPA (#612201, AD; #615745, AR), PLOD1 (#225400, AR), MFN2 (#609260, AD; #617087, AR; #601152, AD), VPS13D (#607317, AR), CELA2A (#618620, AD), SPEN (#619312, AD), CLCNKA (#613090, DR), CLCNKB (#607364, AR; #613090, DR), EPHA2 (#116600, AD)

13

167

1A, 3C, 4C

Likely Pathogenic

BAB3097

3q13.33q21.1

chr3:122157406-123113479

DUP

CASR (#239200, AD/AR; #601198, AD; #145980, AD), CSTA (#607936, AR)

19

2

1A, 3A, 4D

VUS

BAB3097

5p12

chr5:44375961-44815730

DUP

FGF10 (#180920, AD; #149730, AD)

0

2

1A, 2J, 3A, 4D

VUS

BAB3097

5q33.3q34

chr5:158887731-164722046

DUP

IL12B (#614890, AR), GABRB2 (#617829, AD), GABRA1 (#615744, AD), GABRG2 (#618396, AD; #607681, AD)

5

42

1A, 3A, 4D

VUS

BAB3097

9p13.3

chr9:33492358-34725916

TRP

UBAP1 (#618418, AD), MYORG (#618317, AR), DNAI1 (#244400, AR), SIGMAR1 (#614373, AR; #605726, AR), GALT (#230400, AR), IL11RA (#614188, AR)

4

53

1A, 3C, 4D

VUS

BAB3097

17p12p11.2

chr17:11915997-17892664

DUP

DNAH9 (#618300, AR), MYOCD (#618719, AD), ELAC2 (#615440, AR), COX10 (#619046, AR), PMP22 (#139393, AD; #118220, AD; #118300 AD; #145900, AD; #162500, AD; #180800, AD), TTC19 (#615157, AR), PIGL (#280000, AR), TNFRSF13B (#240500, AD/AR), FLCN (#135150, AD; #173600, AD), RAI1 (#182290, AD), SREBF1 (#619016, AD; #158310, AD)

7

110

1A, 2A

Pathogenic

BAB3097

22q13.31p13.32

chr22:47979382-48288823

DUP

 

0

1

1A, 3A, 4D

VUS

mCNV3/BAB9484

1p31.3p31.1

chr1:66885559-77949895

DUP

SLC35D1 (#269250, AR), WLS (#619648, AR), RPE65 (#204100, AR; #613794, AR; #618697, AD), CTH (#219500, AR), TNNI3K (#616117, AD), ACADM (#201450, AR), PIGK (#618879, AR), NEXN (#613122, AD; #613876, AD)

9

108

1A, 3C, 4D

VUS

mCNV3/BAB9484

1q42.2q42.3

chr1:233450789-235471180

DUP

COA6 (#616501, AR), IRF2BP2 (#617765, AD), GGPS1 (#619518, AR), TBCE (#617207, AR; #241410, AR; #244460, AR), B3GALNT2 (#615181, AR)

1

35

1A, 3B, 4D

VUS

mCNV3/BAB9484

2p13.3

chr2:69512973-71153026

DUP

ASPRV1 (#146750, AD), TIA1 (#619133, AD; #604454, AD/AR), FIGLA (#612310, AD), ATP6V1B1 (#267300, AR), MCEE (#251120, AR)

2

44

1A, 3B, 4D

VUS

mCNV3/BAB9484

3q26.32

chr3:176661565-177473432

DUP

TBL1XR1 (#616944, AD; #602342, AD)

1

8

1A, 2A, 3A, 4C

Likely Pathogenic

mCNV3/BAB9484

9q22.2

chr9:89241202-90787598

DUP

SECISBP2 (#609698, AR)

2

38

1A, 3B, 4D

VUS

mCNV3/BAB9484

11p12p11.2

chr11:42871836-44852545

DUP

EXT2 (#133701, AD; #616682, AR), ALX4 (#613451, AR; #609597, AD; #615529, AD)

2

25

1A, 2H, 3B, 4D

VUS

mCNV3/BAB9484

16q22.2

chr16:71219688-71768356

DUP

HYDIN (#608647, AR), TAT (#276600, AR), AP1G1 (#619467, AD)

1

16

1A, 3A, 4D

VUS

mCNV3/BAB9484

20q13.33

chr20:61800345-63644611

DUP

OSBPL2 (#616340, AD), GATA5 (#617912, AD/AR), COL9A3 (#600969, AD), SLC17A9 (#616063, AD), CHRNA4 (#600513, AD), KCNQ2 (#613720, AD; #121200, AD), EEF1A2 (#616409, AD; #616393, AD)

4

15

1A, 3A, 4D

VUS

  1. pLI probability of being Loss‐of‐function Intolerant, AD autosomal dominant, AR autosomal recessive, DR digenic recessive, ACMG American College of Medical Genetics and Genomics, OMIM Online Mendelian Inheritance in Man. *Evidence code based on ACMG consensus recommendation; DUP duplication, TRP Triplication